Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction. Constructive Bio, a pioneering synthetic genomics company, announced...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin advised MiroBio on the deal. MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
